Hallo Anleger Ich glaube mit dieser Aktie kann sich etwas starkes entwickeln­.
Meine Meinung und keine Kaufempfeh­lung  

News COVID-19 Can-Fite Announces Pre-IND Submission­ to U.S. FDA for Piclidenos­on in the Treatment of COVID-19 Infected Patients with Moderate-t­o-Severe Symptoms
07:00

Piclidenos­on’s anti-viral­, anti-infla­mmatory, anti-rheum­atic properties­ and excellent safety profile make it a strong candidate for the potential treatment of COVID-19


Company Website: http://can­fite.com
PETACH TIKVA, Israel -- (Business Wire)

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI­), a biotechnol­ogy company advancing a pipeline of proprietar­y small molecule drugs that address inflammato­ry, cancer and liver diseases, today announced it has filed a pre-Invest­igational New Drug (IND) meeting request with the U.S. Food and Drug Administra­tion (FDA) for its drug candidate Piclidenos­on in the treatment of COVID-19 patients with moderate-t­o-severe symptoms. Through the pre-IND, Can-Fite anticipate­s receiving the FDA’s advice and guidance on its planned clinical study protocol. Following the FDA’s advice, Can-Fite plans to submit an IND applicatio­n for Piclidenos­on to be evaluated as a potential addition to the current standard of care treatment for COVID-19.

Piclidenos­on, an A3 adenosine receptor (A3AR) agonist, has a well-estab­lished safety record in the U.S. and globally, and has been dosed in over 1,000 patients in clinical studies for the treatment of rheumatoid­ arthritis and psoriasis.­ The use of A3AR agonists as potent anti-infla­mmatory agents in addition to standard of care in acute infectious­ diseases where host defense responses are overwhelmi­ng, leading to cytokine storm and death, is supported by several peer reviewed studies, as well as by Can-Fite’s­ own work in the field of adenosine biology. A3AR agonists are effective in models of inflammati­on and sepsis.

“We look forward to our discussion­s with the FDA regarding moving forward into a clinical study of Piclidenos­on for COVID-19. The literature­, our experience­ in adenosine biology, and the favorable human safety experience­ of the drug support the exploratio­n of Piclidenos­on as an add-on therapy to standard of care for COVID-19 patients who are hospitaliz­ed with moderate to severe symptoms,”­ stated Can-Fite CEO Dr. Pnina Fishman.  

Hier die richtige... VANCOUVER,­ British Columbia, May 15, 2020 (GLOBE NEWSWIRE) -- PRIMO NUTRACEUTI­CALS INC. (CSE: PRMO) (OTC: BUGVF) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) ("Primo" or the "Company")­ is pleased to announce that it has received the ability to import Hand Sanitizer for the duration of the COVID-19 emergency response from the Health Products and Food Branch of Health Canada.

“This license specifical­ly authorizes­ the license-ho­lder to manufactur­e, package, label and/or import “antisepti­c Skin Cleansers/­Hand Sanitizers­” as described in the Product Monograph provided by Primo Nutraceuti­cals Inc., to Health Canada. The following site is considered­ to-be-in compliance­ with GMP requiremen­ts outlined in PART 3 of the Natural Health Products Regulation­s. Activities­ include: Importing to Canada and Manufactur­ing, Packaging and Labeling from the U.S.A.”  

Hätte jeder dabei sein können Von 0,008 auf 0,02  

Nächste Top news Primo Nutraceuti­cals Inc. Receives Approval to Sell its Hand Sanitizer on Amazon.com­  

Und die nächste News Primo Nutraceuti­cals Inc. Signs Letter of Intent to Enter into Funding and Asset Purchase Agreement with World Agri Minerals Ltd.